John Vavricka - Jan 31, 2023 Form 4 Insider Report for Atea Pharmaceuticals, Inc. (AVIR)

Role: Chief Commercial Officer
Signature: /s/ Andrea Corcoran, as Attorney-in-Fact for John Vavricka
Stock symbol: AVIR
Transactions as of: Jan 31, 2023
Transactions value $: $0
Form type: 4
Date filed: 2/2/2023, 05:26 PM
Previous filing: Feb 2, 2022
Next filing: Feb 2, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AVIR	Restricted Stock Units	Award	$0	+100K		$0.00	100K	Jan 31, 2023	Common Stock	100K		Direct	F1, F2
transaction	AVIR	Stock Option (Right to Buy)	Award	$0	+140K		$0.00	140K	Jan 31, 2023	Common Stock	140K	$4.63	Direct	F3

Showing 1 to 2 of 2 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2	The RSUs vest in three (3) equal annual installments on the first three anniversaries of the grant date such that the RSUs are fully vested on January 31, 2026.
F3	The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2023 such that the option is fully vested on January 31, 2027.